

Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV0639US01		APPLICATION NO.: 10/791,979	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Duane A. Burnett et al.			
				FILING DATE: 03/03/2004		GROUP: 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
	AM						
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AQ	Copy of International Search Report for International Application No. PCT/US2004/006656 (04/08/2004) - 5 Pages					
	AR						
	AS						
	AT						
	AU						
	AV						
EXAMINER				DATE CONSIDERED			
mmw Ben				8 4/1/06			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

1/18/05

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2001. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/791,979
				Filing Date	March 3, 2004
				First Named Inventor	Duane Burnett et al.
				Group Art Unit	1624
				Examiner Name	Mark L. Berch
Sheet	1	of	2	Attorney Docket Number	CV06039US/4686-050108

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ²			
		N/A				

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Office ³	Number ³	Kind Code ³				
MB	1	WO	99/22728	A1	Arch Development Corporation	May 14, 1999		
MB	2	WO	01/96347	A1	Bristol-Myers Squibb Company	December 20, 2001		

Examiner Signature	<i>Man (Ber)</i>	Date Considered	4/1/06
--------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/791,979
				Filing Date	March 3, 2004
				First Named Inventor	Duane Burnett et al.
				Group Art Unit	1624
				Examiner Name	Mark L. Berch
Sheet	2	of	2	Attorney Docket Number	CV06039/4686-050108

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
NB	3	Luis Gruberg, MD, "Inflammatory Markers in Acute Coronary Syndromes: C-reactive Protein (CRP) and Chlamydia," American Heart Association Scientific Sessions 2000.	

Examiner Signature	<i>Mark Berch</i>	Date Considered	4/1/06
--------------------	-------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet 1 of 16

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV6039US01

APPLICATION NO.:

10/791,979

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:

Duane A. Burnett et al.

FILING DATE:

03/03/2004

GROUP:

1614

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATIO N	
							YES	N O
	AA	BE 884722 A	12/01/80	BELGIUM	C07D	AG1K	X(abs.)	
	AB	CA 2253769	11/29/99	CANADA	A61K	31/22		
	AC	DE 2046823 A	03/30/72	GERMANY	C07C		X(abs.)	
	AD	DE 2521113 A	03/18/76	GERMANY	C07C	87/34	X(abs.)	
	AE	EP 0002151 A1,B1	05/30/79	EUROPE	C07C	69/67		
	AF	EP 0010299 B1	02/15/84	EUROPE	A61K	45/06		
	AG	EP 0179559 A2	04/30/86	EUROPE	C07D	405/06		
	AH	EP 0199630 A1	10/29/86	EUROPE	C07D	205/08		
	AI	EP 0199630 B1	09/19/90	EUROPE	C07D	205/08		
	AJ	EP 0264231 A1	04/20/88	EUROPE	C07D	205/08		
	AK	EP 0266896 B1	05/11/88	EUROPE	C07D	471/04		
	AL	EP 0274873 B1	07/20/88	EUROPE	C07K	11/00		
	AM	EP 0288973 B1	11/02/88	EUROPE	C07D	417/06		
	AN	EP 0311366 B1	04/12/89	EUROPE	C07D	471/04		
	AO	EP 0333268 A1	09/20/89	EUROPE	C07F	7/18		
	AP	EP 0337549 A1	10/18/89	EUROPE	C07D	205/08		
	AQ	EP 0337549 B1	10/04/95	EUROPE	C07D	205/08		
	AR	EP 0365364 A2	04/25/90	EUROPE	C07D	205/08		
	AS	EP 0369686 A1	05/23/90	EUROPE	C07D	463/00		
	AT	EP 0375527 A1	06/27/90	EUROPE	C07D	205/08	X(abs.)	
	AU	EP 0401705 A3	12/12/90	EUROPE	A61K	31/66		
	AV	EP 0415487 A2	03/06/91	EUROPE	C07D	205/08		
	AW	EP 0455042 A1	11/06/91	EUROPE	A61K	31/19		
	AX	EP 0457514 A1	11/21/91	EUROPE	A61K	45/06		
	AY	EP 0457514 B1	08/21/96	EUROPE	A61K	45/06		
	AZ	EP 0461548 A3	12/18/91	EUROPE	A61K	31/365		
	BA	EP 0462667 A2	12/27/91	EUROPE	C07D	205/08		
	BB	EP 0475148 A1	03/18/92	EUROPE	A61K	31/215		
	BC	EP 0475755 B1	03/18/92	EUROPE	C07D	403/06		
	BD	EP 0481671 A1	04/22/92	EUROPE	C07D	205/08		
	BE	EP 0482498 A3	04/29/92	EUROPE	A61K	31/66		
	BF	EP 0524595 A1	01/27/93	EUROPE	C07D	205/08		
	BG	EP 0720599 B1	07/10/96	EUROPE	C07D	205/08		
	BH	EP 0793958 A2	09/10/97	EUROPE	A61K	9/16	X(abs)	
	BI	EP 0814080 A1	12/29/97	EUROPE	C07D	267/14		
	BJ	EP 0904781 A2	03/31/99	EUROPE	A61K	31/215		
	BK	EP 1048295 A2	11/02/00	EUROPE	A61K	31/216		
	BL	FR 1103113	10/31/55	FRANCE				X
	BM	FR 2779347	12/10/97	FRANCE	A61	31/215	X(abs.)	
	BN	GB 861367	02/22/61	GB	A61K			
	BO	GB 902658	08/09/62	GB	C07D			
	BP	GB 1415295	11/26/75	GB	C07C	59/26		

Man Ben

4/1/05

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01		APPLICATION NO.: 10/791,979	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.			
				FILING DATE: 03/03/2004		GROUP: 1614	
FOREIGN PATENT DOCUMENTS							
M	BQ	GB 2329334 A	03/24/99	GB	A61K	45/00	
	BR	JP 028057	10/01/81	JAPAN			X(abs.)
	BS	JP 121479	12/10/86	JAPAN			X(abs.)
	BT	JP 136485	05/26/81	JAPAN			X(abs.)
	BU	JP 180212	03/24/86	JAPAN			X(abs.)
	BV	JP 219681	04/14/87	JAPAN			X(abs.)
	BW	JP 5194209 A	08/03/93	JAPAN	A61K	031/22	X(abs.)
	BX	JP 5239020 A	1993	JAPAN	C07D	205/08	X(abs.)
	BY	JP 4054182 A	1992	JAPAN	C12P	017/16	X(abs.)
	BZ	JP 63017859 A	1988	JAPAN	C07D	205/08	X(abs.)
	CA	JP 4266869 A	1992	JAPAN	C07D	205/08	X(abs.)
	CB	JP 4356195 A	1993	JAPAN			X(abs.)
	CC	JP 4356495	12/10/92	JAPAN			X(abs.)
	CD	JP 5058993 A	1993	JAPAN			X(abs.)
	CE	JP 61280295 A	1987	JAPAN			X(abs.)
	CF	JP 95051558 B2	06/05/95	JAPAN	C07D	205/08	X(abs.)
	CG	JP 91068020	10/25/91	JAPAN	C07D	205/08	X(abs.)
	CH	JP 94047573	06/22/94	JAPAN	C07D	205/08	X(abs.)
	CI	WO 82/01649	05/27/82	PCT	A61K	9/52	X(abs.)
	CJ	WO 87/04429	07/30/87	PCT	C07D	205/08	
	CK	WO 88/04656	06/30/88	PCT	C07D	405/04	
	CL	WO 88/05296	07/28/88	PCT	A61K	31/365	
	CM	WO 91/03249	03/21/91	PCT	A61K	31/785	X(abs.)
	CN	WO 92/13837	08/20/92	PCT	C07D	205/08	
	CO	WO 93/02048	02/04/93	PCT	C07D	205/08	
	CP	WO 93/07167	04/15/93	PCT	C07J	71/00	
	CQ	WO 93/11150	06/10/93	PCT	C07J	71/00	
	CR	WO 94/00480	01/06/94	PCT	C07J	71/00	
	CS	WO 94/14433	07/07/94	PCT	A61K	31/395	
	CT	WO 94/17038	08/04/94	PCT	C07D	205/12	
	CU	WO 94/20535	09/15/94	PCT	C07K	13/00	
	CV	WO 95/04533	02/16/95	PCT	A61K	31/445	
	CW	WO 95/06470	03/09/95	PCT	A61K	31/435	
	CX	WO 95/08532	03/30/95	PCT	C07D	205/08	
CY	WO 95/18143	07/6/95	PCT	C07J	71/00		
CZ	WO 95/26334	10/05/95	PCT	C07D	205/08		
DA	WO 95/28919	11/02/95	PCT	A61K	31/19	X(abs.)	
DB	WO 95/35277	12/28/95	PCT	C07D	205/08		
DC	WO 96/00288	01/04/96	PCT	C12N	15/12		
DD	WO 96/09827	04/04/96	PCT	A61K	31/58		
DE	WO 96/16037	05/30/96	PCT	C07D	205/08		

Man Ben

04/1/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01		APPLICATION NO.: 10/791,979	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett, et al.			
				FILING DATE: 03/03/2004		GROUP: 1614	
FOREIGN PATENT DOCUMENTS							
<i>AD</i>	DF	WO96/19450	06/27/96	PCT	C07D	205/08	
	DG	WO 96/19987	07/04/96	PCT	A61K	31/35	
	DH	WO 96/40255	12/19/96	PCT	A61K	45/06	
	DI	WO 97/16455	05/09/97	PCT	C07H	3/04	
	DJ	WO 97/18304	05/22/97	PCT	C12N	15/00	
	DK	WO 97/25042	07/17/97	PCT	A61K	31/42	
	DL	WO 97/28149	08/07/97	PCT	C07D	307/79	
	DM	WO 97/31907	09/04/97	PCT	C07D	263/56	
	DN	WO 97/35576	10/02/97	PCT	A61K	31/44	
	DO	WO 97/46238	12/11/97	PCT	A61K	31/245	
	DP	WO 98/01100	01/15/98	PCT	A61K		
	DQ	WO 98/05331	02/12/98	PCT	A61K	31/45	
	DR	WO 98/14179	04/09/98	PCT	A61K	9/50	
	DS	WO 98/31360	07/23/98	PCT	A61K	31/19	
	DT	WO 98/31361	07/23/98	PCT	A61K	31/215	X(abs.)
	DU	WO 98/31366	07/23/98	PCT	A61K	31/445	
	DV	WO 98/43081	10/01/98	PCT	G01N	33/50	
	DW	WO 98/46215	10/22/98	PCT	A61K	9/20	
	DX	WO 98/47518	10/29/98	PCT	A61K	31/715	
	DY	WO 98/57652	12/23/98	PCT	A61K	31/785	
	DZ	WO 99/04815	04/02/99	PCT	A61K	45/00	X(abs.)
	EA	WO 99/06035	02/11/99	PCT	A61K	31/00	
	EB	WO 99/06046	02/11/99	PCT	A61K	31/455	
	EC	WO 99/08501	2/25/99	PCT			
	ED	WO 99/09967	03/04/99	PCT	A61K	31/00	
	EE	WO 99/12534	03/18/99	PCT	A61K	31/17	X(abs.)
	EF	WO 99/11260	03/11/99	PCT	A61K	31/40	
	EG	WO 99/15159	04/01/99	PCT	A61K	31/00	
	EH	WO 99/15520	04/01/99	PCT	C07D	319/20	X(abs.)
	EI	WO 99/18072	04/15/99	PCT	C07D	205/08	
	EJ	WO 99/20275	04/29/99	PCT	A61K	31/47	
	EK	WO 99/20614	04/29/99	PCT	C07D	265/36	
	EL	WO 99/29300	06/17/99	PCT	A61K	9/107	
	EM	WO 99/38498	08/05/99	PCT	A61K	31/00	
	EN	WO 99/38845	08/05/99	PCT	C07D	213/65	
	EO	WO 99/38850	08/05/99	PCT	C07D	237/32	
	EP	WO 99/46232	09/16/99	PCT	C07C	62/34	X(abs.)
	EQ	WO 99/47123	09/23/99	PCT	A61K	9/16	
	ER	WO 99/48488	09/30/99	PCT	A61K	31/00	
<i>AD</i>	ES	WO 99/66929	12/29/99	PCT	A61K	31/405	

Mark Burr 4/1/09

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01		APPLICATION NO.: 10/791,979	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.			
				FILING DATE: 03/03/2004		GROUP: 1614	
FOREIGN PATENT DOCUMENTS							
mb	ET	WO 99/66930	12/29/99	PCT	A61K	31/405	
	EU	WO 00/04011	01/27/00	PCT	C07D	319/06	
	EV	WO 00/07617	02/17/00	PCT	A61K	38/26	
	EW	WO 00/16749	03/30/00	PCT	A61K	9/16	X(abs.)
	EX	WO 97/21676	06/19/97	PCT	C07D	205/09	
	EY	WO 97/41098	11/06/97	PCT	C07D	205/09	
	EZ	WO 00/18395	04/06/00	PCT	A61K	31/215	
	FA	WO 00/20623	04/13/00	PCT	C12P	41/00	
	FB	WO 00/23415	04/27/00	PCT	C07C	69/734	
	FC	WO 00/23416	04/27/00	PCT	C07C	69/734	
	FD	WO 00/23425	04/27/00	PCT	C07D	209/80	
	FE	WO 00/23445	04/27/00	PCT	C07D	471/12	
	FF	WO 00/23451	04/27/00	PCT	C07D	487/14	
	FG	WO 00/28981	05/25/00	PCT	A61K	31/00	
	FH	WO 00/31548	06/02/00	PCT	G01N	33/68	
	FI	WO 00/32189	06/08/00	PCT	A61K	31/415	
	FJ	WO 00/34240	06/15/00	PCT	C07D	205/08	
	FK	WO 00/37057	06/29/00	PCT	A61K	9/48	
	FL	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)
	FM	WO 00/38721	07/06/00	PCT	A61K	45/06	
	FN	WO 00/38722	07/06/00	PCT	A61K	45/06	
	FO	WO 00/38723	07/06/00	PCT	A61K	45/06	
	FP	WO 00/38724	07/06/00	PCT	A61K	45/06	
	FQ	WO 00/38725	07/06/00	PCT	A61K	45/06	
	FR	WO 00/38726	07/06/00	PCT	A61K	45/06	
	FS	WO 00/38727	07/06/00	PCT	A61K	45/06	
	FT	WO 00/38728	07/06/00	PCT	A61K	45/06	
	FU	WO 00/38729	07/06/00	PCT	A61K	45/06	
	FV	WO 00/40247	07/13/00	PCT	C07D	265/26	
	FW	WO 00/45817	08/10/00	PCT	A61K	31/505	
FX	WO 00/50392	08/31/00	PCT	C07C	323/52	X(abs.)	
FY	WO 00/53149	09/14/00	PCT	A61K			
FZ	WO 00/53173	09/14/00	PCT	A61K	31/22		
GA	WO 00/53563	09/14/00	PCT	C07C	59/92	X(abs.)	
GB	WO 00/56403	09/28/00	PCT	A61P	9/10		
GC	WO 00/57859	10/05/00	PCT	A61K	9/48		
GD	WO 00/57918	10/05/00	PCT	A61K	47/44		
GE	WO 00/60107	10/12/00	PCT	C12P	17/10		
GF	WO 00/63153	10/26/00	PCT	C07C	69/734		
GG	WO 00/63161	10/26/00	PCT	C07C	237/30		

Man Uzer 4/1/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01		APPLICATION NO.: 10/791,979	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.			
				FILING DATE: 03/03/2004		GROUP: 1614	
FOREIGN PATENT DOCUMENTS							
MB	GH	WO 00/63190	10/26/00	PCT	C07D	265/38	
	GI	WO 00/63196	10/26/00	PCT	C07D	277/04	
	GJ	WO 00/63209	10/26/00	PCT	C07D	471/04	
	GK	WO 00/63703	10/26/00	PCT	G01N	33/92	
	GL	WO 00/69412	11/23/00	PCT	A61K	9/127	
	GM	WO 00/69445	11/23/00	PCT	A61K	31/785	
	GN	WO 00/72825	12/7/00	PCT	A61K	9/14	
	GO	WO 00/72829	12/07/00	PCT	A61K	9/48	
	GP	WO 00/75103	12/14/00	PCT	C07C	235/60	X(abs.)
	GQ	WO 00/76482	12/21/00	PCT	A61K	9/48	
	GR	WO 00/76488	12/21/00	PCT	A61K	31/00	
	GS	WO 00/78312	12/28/00	PCT	A61K	31/421	
	GT	WO 00/78313	12/28/00	PCT	A61K	31/422	
	GU	WO 01/00579	01/04/01	PCT	C07D	213/65	
	GV	WO 01/00603	01/04/01	PCT	C07D	277/24	
	GW	WO 01/08686	02/08/01	PCT	A61K	31/495	
	GX	WO 01/12176	02/22/01	PCT	A61K	31/16	
	GY	WO 01/12187	02/22/01	PCT	A61K	31/404	
	GZ	WO 01/12612	02/22/01	PCT	C07D	257/04	
	HA	WO 01/14349	03/01/01	PCT	C07D	277/34	X(abs.)
	HB	WO 01/14350	03/01/01	PCT	C07D	277/34	X(abs.)
	HC	WO 01/14351	03/01/01	PCT	C07D	277/34	X(abs.)
	HD	WO 01/15744	03/08/01	PCT	A61K	49/00	
	HE	WO 01/16120	03/08/01	PCT	C07D	263/32	
	HF	WO 01/17994	03/15/01	PCT	C07D	413/12	
	HG	WO 01/18210	03/15/01	PCT	C12N	15/12	
	HH	WO 01/21181	03/29/01	PCT	A61K	31/675	X(abs.)
	HI	WO 01/21259	03/29/01	PCT	A61P		
	HJ	WO 01/21578	03/29/01	PCT	C07C	235/60	X(abs.)
	HK	WO 01/21647	03/29/01	PCT	C07K	14/00	
HL	WO 01/22962	04/05/01	PCT	A61K	31/435		
HM	WO 01/25225	04/12/01	PCT	C07D	317/18		
HN	WO 01/25226	04/12/01	PCT	C07D	327/04		
HO	WO 01/30343	05/03/01	PCT	A61K	31/40		
HP	WO 01/32161	05/10/01	PCT	A61K	31/00		
HQ	WO 01/35970	05/25/01	PCT	A61K	35/76		
MB	HR	WO 01/40192	06/07/01	PCT	C07D	217/26	X(abs.)

Man U Bern 4/1/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01		APPLICATION NO.: 10/791,979	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.			
				FILING DATE: 03/03/2004		GROUP: 1614	
FOREIGN PATENT DOCUMENTS							
mg	HS	WO 01/45676	06/28/01	PCT	A61K	9/24	
	HT	WO 01/49267	07/12/01	PCT	A61K	9/14	
	HU	WO 01/64221	09/07/01	PCT	A61K	31/52	
	HV	WO 01/76632	10/18/01	PCT	A61K	45/06	
	HW	WO 02/50090	06/27/02	PCT	C07H	15/26	
	HX	WO 02/058696	08/01/02	PCT	A61K	31/397	
	HY	WO 02/058731	08/01/02	PCT	A61K	45/06	
	HZ	WO 02/058732	08/01/02	PCT	A61K	45/06	
	IA	WO 02/058733	08/01/02	PCT	A61K	45/06	
	IB	WO 02/058734	08/01/02	PCT	A61K	45/06	
	IC	WO 02/058685	08/01/02	PCT	A61K	31/00	
	ID	WO 02/064130	08/22/02	PCT	A61K	31/195	
	IE	WO 02/064549	08/22/02	PCT	C07C	275/34	
	IF	WO 02/064664	08/22/02	PCT	C08G	77/02	
	IG	WO 02/072104	09/19/02	PCT	A61K	31/54	
	IH	WO 02/081454	10/17/02	PCT	C07D	239/36	
	II	WO 02/26729	04/04/02	PCT	C07D	311/66	
	IJ	WO 02/064094	08/22/02	PCT	A61K		
	IK	WO 02/50027	06/27/02	PCT			
	IL	WO 02/50060	06/27/02	PCT			
IM	WO 02/50068	06/27/02	PCT				
IN	WO 94/26738	11/24/94	PCT				
IO	EP 1 036 563 A1	09/20/00	EPO				
IP	EP 0 753 298 A1	01/15/97	EPO				
IQ	WO 01/34148	05/17/01	PCT				
IR	WO 01/60807	08/23/01	PCT				
IS	WO 02/08188	01/31/02	PCT				
IT	WO 03/039542	05/15/03	PCT				
IU	WO 03/074101	09/12/03	PCT				
IV	WO 03/088962	10/30/03	PCT				
IW	WO 03/018024	03/06/03	PCT	A61K	31/55		
IX	WO 03/018059	03/06/03	PCT	A61K	45/06		

Mark U. Buel

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV06039US01	SERIAL NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>			APPLICANT: Duane A. Burnett et al.	
			FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
MB	IY	Exhibit A: SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary		
	IZ	Exhibit B: SCH 58235 (ezetimibe), Drug Formulation Development Summary		
	JA	Exhibit C: SCH 58235 (ezetimibe), Drug Formulation Development Summary		
	JB	Exhibit D: SCH 58235 (ezetimibe), Drug Formulation Development Summary		
	JC	Exhibit E: SCH 58235 (ezetimibe), Drug Formulation Development Summary		
	JD	Exhibit F: SCH 58235 (ezetimibe), Drug Formulation Development Summary		
	JE	Exhibit G: SCH 58235 (ezetimibe), Drug Formulation Development Summary		
	JF	Exhibit H: SCH 58235 (ezetimibe), Drug Formulation Development Summary		
	JG	Exhibit 1: Master Sheet for the SCH 58235 and Lovastatin Research Study, <i>Schering-Plough Research Institute</i> (Protocol No. C906-411), page 1576-1585		
	JH	Exhibit 2: Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, <i>Peninsular Testing Corporation</i> , page 106-112		
	JI	Exhibit 3: Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," <i>Schering-Plough Research Institute</i> (Protocol No. C98-010), page 1558-1566		
	JJ	Exhibit 4: Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, <i>Peninsular Testing Corporation</i> , page 124-130		
	JK	Exhibit 5: Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," <i>Schering-Plough Research Institute</i> , page 1-8		
	JL	Vaccaro, W.D. <i>et al.</i> , "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" <i>Bioorganic & Medicinal Chemistry Ltrs., Oxford, G.B.</i> , 8:313-318 (1998)		
	JM	Vaccaro, W.D. <i>et al.</i> , "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", <i>Bioganic & Medicinal Chem. Ltrs. Oxford, G.B.</i> 8:319-322 (1998)		
	JN	H. Davis <i>et al.</i> , "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", <i>Arterioscler, Thromb. Vasc. Biol</i> 21:2032-2038, (Dec. 2001)		
	JO	Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", <i>Chemical Abstracts No. 15</i> , 86 (April 11, 1997)		
	JP	Otto <i>et al.</i> , "Stereochemistry of dehydration and halogenation fo αR^* and αS^* isomeric 3-(α -hydroxybenzyl)-1,4 diphenyl-2 azetidinones, <i>Chemical Abstracts No. 19</i> , 99 (Nov. 7, 1983)		
	JQ	T. Durst <i>et al.</i> , "Metallation of N-Substituted β -Lactams. A Method of the Introduction of 3-substituents into β -Lactams" <i>Canadian Journal of Chemistry</i> , 50:3196-3201 (1971)		
JR	Nobuki, O. <i>et al.</i> , "Stereoselective syntheses of b-lactam derivatives by ultrasound promoted Reformatskii reaction" <i>Chemical Abstracts No. 106</i> , 17 (April 27, 1987)			
NB	JS	M. Hoekman, <i>et al.</i> , "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ -Lactones", <i>J. Agric. Food Chem.</i> , 30:920-024 (1982)		

Wm B. 4/1/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV06039US01	APPLICATION NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>			APPLICANT: Duane A. Burnett, et al.	
			FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
WAB	JT	H. Otto <i>et al.</i> "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidononen", <i>Liebigs Ann. Chem.</i> 1152-1161 (1983)		
	JU	G. George <i>et al.</i> "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" <i>Tetrahedron Letters</i> , 26:3903-3906 (1985)		
	JV	Hart <i>et al.</i> "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", 26 <i>Tetrahedron Letters</i> , 45:5493-5496 (1985)		
	JW	Panfil, I. <i>et al.</i> "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" 24 <i>Heterocycles</i> 6:1609-1617 (1986)		
	JX	D. Roger Illingworth, "An Overview of Lipid-Lower Drugs" <i>Drugs</i> 36:63:71 (1988)		
	JY	Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" <i>Circulation</i> 80:1101-1114 (1989)		
	JZ	B. Ram <i>et al.</i> "Potential Hypolipidemic agents: Part V", 29B Indian J. Chem. 1134-37 (1990)		
	KA	Schnitzer-Polokoff, R. <i>et al.</i> , "Effects of Acyl-CoA: Choleseraol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" <i>Comp. Biochem. Physiol.</i> 99A:665-670 (1991)		
	KB	Horie, M. <i>et al.</i> , "Hypolipidemic effects of NB-598 in dogs" <i>Atherosclerosis</i> 88:183-192 (1991)		
	KC	Baxter, A., "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", <i>The Journal of Biological Chemistry</i> 267:11705-11708 (1992)		
	KD	Summary Factfile, "Anti-Antherosclerotic Agents" <i>Current Drugs Ltd.</i> (1992)		
	KE	Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tigogenin cellobioside (CP-88818; tiqueside) 1" <i>Journal of Lipid Research</i> 34:377-395 (1993)		
	KF	Salisbury, B. <i>et al.</i> , "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" <i>Atherosclerosis</i> 115:45-63 (1995)		
	KG	Clader, J. W. <i>et al.</i> , "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Viro Activity" <i>Journal of Medicinal Chemistry</i> 38:1600-1607 (1995)		
	KH	Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" <i>Atherosclerosis</i> pp. 311-315 (1995)		
	KI	Vaccaro, W, <i>et al.</i> , "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", <i>Bioorg. & Med. Chem.</i> 6:1429-1437 (1998)		
KJ	G. Wu <i>et al.</i> , "A Novel One-Step Diastereo- and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (4/21/99).			
KK	B. Staels, "New Roles for PPARS in Cholesterol Homeostasis", <i>Trends in Pharmacological Sciences</i> , 22:9 p. 444 (Sept. 2001)			
KL	Abbott <i>et al.</i> , "Tricor® Capsules, Micronized", <i>Physicians Desk Reference</i> , January 8, 2001.			
WM	KM	M. Feher <i>et al.</i> , 1991, <i>Lipids and Lipid Disorders</i> , p.1-87 (1991).		

Mark Beon

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01	APPLICATION NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.	
				FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	KN	M. Ricote <i>et al.</i> , "New Roles for PPARs in Cholesterol Homeostasis", <i>Trends in Pharmacological Science</i> , Vol. 22, No. 9 44-443 (2001)			
	KO	C. Dujovne <i>et al.</i> , "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", <i>J. Clin. Pharm.</i> 41:1 70-78 (Jan. 2001)			
	KP	W. Oppolzer <i>et al.</i> , "Asymmetric Diels - Alder Reactions, Facile Preparation and Structure of Sulfonamido - Isobornyl Acrylates", <i>Tetrahedron Letters</i> No. 51, 25:5885-5888 (1984).			
	KQ	M. Davidson <i>et al.</i> , "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", <i>Expert Opinion Investigating Drugs</i> , 11:2663-71, (Nov. 2000)			
	KR	M. Davidson <i>et al.</i> , "Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal effects", 159 <i>Arch. Intern. Med.</i> 16 1893-900 (Sept. 1999)			
	KS	I. Wester, "Cholesterol - Lowering effect of plant sterols", <i>Euro. J. Lipid, Sci. Tech.</i> 37-44 (2000).			
	KT	A. Andersson <i>et al.</i> , "Cholesterol -lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowering diet", 1 <i>European Heart. J. Supplements</i> S80 - S90 (1999)			
	KU	H. Gylling <i>et al.</i> , "Reduction of Serum Cholesterol in Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostanol Ester Margarine, 96 <i>Circulation</i> 12 4226-4231 (Dec. 16, 1997)			
	KV	T. Miettinen <i>et al.</i> , "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", <i>New England Journal of Med.</i> 333 1308-1312 (Nov. 16, 1995)			
	KW	T. Bocan <i>et al.</i> , "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", <i>Arterioscler Thromb Vasc. Biol.</i> 70-79 (Jan. 2000)			
	KX	M. Van Heek <i>et al.</i> , "In Vivo Metabolism - Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," 283 <i>J. Pharma and Experimental Therapeutics</i> 1 157-163 (1997)			
	KY	H. Davis <i>et al.</i> , "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," 151 <i>Atherosclerosis</i> 1:133 (July 2000)			
	KZ	L. Nguyen <i>et al.</i> , "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", 10 <i>Atherosclerosis</i> 2, 289-297 (1990)			
	LA	L. Nguyen <i>et al.</i> , "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and dietary sterol restriction," 32 <i>J. Lipid Res.</i> 1941-1948 (1991)			
LB	M. Cobb <i>et al.</i> , "Sitosterolemia: Opposing Effects of cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," 45 <i>Metabolism</i> 6 673-679 (June 1996)				



Manu Beer 4/1/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01	APPLICATION NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.	
				FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
my	LC	M. Huettinger <i>et al.</i> , "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", <i>13 Arteriosclerosis and Thrombosis</i> 7 1005-1012 (July 1993).			
	LD	J. Best <i>et al.</i> , "Diabetic Dyslipidaemia", <i>59 Drugs</i> 5 1101-1111 (May 2000)			
	LE	P. Chong, <i>et al.</i> , "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", <i>60 Drugs</i> 1 55-93 (July 2000)			
	LF	M. Brown <i>et al.</i> , "A Receptor - Mediated Pathway for Cholesterol Homeostasis", <i>232 Science</i> 34-47 (April 4, 1986)			
	LG	L. Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", <i>JACC</i> 257A (Feb. 2000)			
	LH	Medical Economics, Co., Inc., <i>Physician's Desk Reference</i> , 207-208, 2054 (55 th Ed. 2001)			
	LI	K. Fassbender <i>et al.</i> , "Simvastatin Strongly Reduces Levels of Alzheimer's Disease β -Amyloid Peptides A β 42 and A β 40 in vitro and in vivo", <i>PNAs Early Edition</i> , www.phas.org/cgi/doi/10.1073/phas.081620098 (2001)			
	LJ	Andrx Announces Results of Alzheimer's Disease Clinical Study", <i>Andrx Corporate Release</i> (April 11, 2001)			
	LK	Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130", <i>US Bancorp Piper</i> , April 12, 2001			
	LL	Statins May Protect Against Alzheimer's Disease; much research needed", <i>Geriatrics</i> February 2001			
	LM	Dementia and Statins", <i>The Lancet</i> March 17, 2001			
	LN	Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers", <i>Reuters</i> April 11, 2001			
	LO	Cholesterol Drugs Ease Alzheimer's Damage; www.usatoday.com April 10, 2001			
	LP	Lovastatin XL of Use in Alzheimer's? <i>News Edge</i> (May 2, 2001)			
	LQ	L. Refolo <i>et al.</i> , "Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model", <i>Neurobiology of Disease</i> 321-331 (2000)			
	LR	D. Kang <i>et al.</i> , "Modulation of Amyloid β -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor - Related Protein Pathway", <i>Journal of Clinical Investigation</i> 106:9, 1159-1166 (Nov. 2000)			
	LS	Y.A. Kesaniemi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", <i>J. Clin. Invest.</i> 80(2) 578-81 (Aug. 1987)			
	LT	J. Busciglio <i>et al.</i> , "Generation of β -amyloid in the secretory pathway in neuronal and nonneuronal cells", <i>90 Proc. Nat'l. Acad. Sci, USA</i> , 2092-2096 <i>Neurobiology</i> (March 1993)			
	LU	L. Farrer <i>et al.</i> , "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", <i>Annals of Neurology</i> 25:5, 485-493 (May 1989)			
LV	A. Goate <i>et al.</i> , "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", <i>349 Nature No.</i> 6311, 704-706 (Feb. 21, 1991)				

Mon Dord 4/1/00

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01	APPLICATION NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.	
				FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
MB	LW	D. Mann <i>et al.</i> , "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", 89 <i>J. Neuro. Sci.</i> , 169-179 (Feb. 1989)			
	LX	G. McKhann <i>et al.</i> , "Clinical Diagnosis of Alzheimer's Disease", 34 <i>Neurology</i> No. 7, 939-944 (July 1984)			
	LY	D. Selokoe, "Alzheimer's Disease: Genotypes, Pheontype and Treatments", 275 <i>Science</i> , 630-631 (Jan. 31, 1997)			
	LZ	C. Van Duijn, <i>et al.</i> , "Familial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", 20 <i>Int'l J. Epidemiology</i> No. 2 (Suppl. 2), 513-520 (1991)			
	MA	T Nagahara <i>et al.</i> , "Dibasic (Amidcinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", <i>J. Med. Chem</i> 37:1200-1207 (1994)			
	MB	Mellott <i>et al.</i> , "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistatin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <i>Circulation Research</i> , 70:1152-1160 (1992)			
	MC	Sitko <i>et al.</i> , "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", <i>Circulation</i> , 85:808-815 (1992)			
	MD	Seymour <i>et al.</i> , 1994, <i>Biochemistry</i> , 33:3949-3959			
	ME	Markwardt, 1994, <i>Thrombosis and Hemostasis</i> , 72:477-479			
	MF	Mendall <i>et al.</i> , "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", <i>BMJ</i> ; 312:1061-1065 (April 27, 1996)			
	MG	Ridker P. <i>et al.</i> , "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", 46 <i>J. Investig. Med.</i> ; 8:391-395 (1998)			
	MH	Waters, D. <i>et al.</i> , "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", <i>Circulation</i> ; 82:1940-1953 (1990)			
	MI	Fleckenstein, 1985, <i>Cir. Res.</i> Vol 52 (Suppl. 1) 13-16			
	MJ	Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", <i>John Wiley, New York</i> , pp. 286-313			
	MJ	McCall, D., 1985, "Curr. Pract. Cardiol. Vol. 10, 1-11			
	ML	Remington 1995, "The Science and Practice of Pharmacy, (19 th Ed. 1995) p. 963			
	MM	M. Chistie <i>et al.</i> , "Early - Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", 276 <i>J. Biol. Chem.</i> No. 24; 21562-70 (June 15, 2001)			
	MN	C. Janus <i>et al.</i> , "A β Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", 408 <i>Nature</i> 21/28; 979-982 (Dec. 2000)			
	MO	Manual of Laboratory Operations, "Lipid Research Clinics Program Report, Washington, D.C., U.S. Dept. of Health, Education and Welfare Publication; 1:75-628 (1974)			
MB	MP	Steiner, PM <i>et al.</i> , "Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract], <i>J. Clin. Chem. Clin. Biochem</i> ; 19:850 (1981)			


Mm Berl 4/1/00

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01	APPLICATION NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.	
				FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	MQ	Steele WG, et al., "Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique, 22 Clin. Chem.; 1:98-101 (1976)			
	MR	Salen et al., "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Cholesterol Syntheses in Sitosterolemia with Xanthomatosis", J. Lipid Res.; 30:1319-1330 (1989)			
	MS	Lutjohann et al., "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", J. Lipid Res.; 36:8; 1763-1773 (1995)			
	MT	Zhang et al., "Calpain Inhibitor I Increases B- Amyloid Peptide by Inhibiting the Degradation of the Substrate of γ - Secretase" 274 J. Biol. Chem., 13:8966-8972 (1999)			
	MU	Zhang et al., "Biochemical Characterization of the γ -Secretase Activity that Produces B- Amyloid Peptides", Biochemistry 40:5049-5055 (2001)			
	MV	Ida et al., "Analysis of Heterogeneous BA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", 271 J. Biol. Chem.; 37:22908-22914 (1996)			
	MW	Lichtlen, P.R. et al., 1990, Lancet, 335:1109-1113			
	MX	Bays et al., "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies", Clinical Therapeutics, 23:1209-1230 (2001)			
	MY	E. Leitersdorf et al., "Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management", European Heart Journal Supplement, 3:E17-E23 (June 2001)			
	MZ	Bauer et al., "Ezetimibe Does not Affect the Pharmacokinetics or Pharmacodynamics of Warfarin", Clinical Pharmacology and Therapeutics, 69:2 p5 (Mar. 6-10, 2001)			
	NA	Keung et al., "Ezetimibe Does Not Affect the Pharmacokinetics of oral Contraceptives, Clinical Pharmacology and Therapeutics, 69:2 p55 (Mar. 6-10, 2001)			
	NB	Kosoglou et al., "Pharmacodynamic interaction between fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", Workshops Lipid Lowering Drugs 72 nd EAS Congress, p. 38 (May 21-23, 2001)			
	NC	T. Kosoglou et al., "Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects On Apo CII and LDL Subfractions", Posters 11. Lipid Lowering Drugs/Novel, 72 nd EAS Congress, p. 89 (May 21-23, 2001)			
	ND	L. Reyderman et al., "Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Gemfibrozil", Presented at XIV Int'l Symp. on Drugs Affecting Lipid Metabolism (DALM) N.Y. (Sept. 9-12, 2001)			
	NE	P. Statkevich et al., "Ezetimibe Does Not Affect the Pharmacokinetics and Pharmacodynamics of Glipizide", Clinical Pharmacology & Therapeutics, 69:67 (March 6-10, 2001)			
	NF	Knopp et al., "Effect of Ezetimibe on Serum Concentrations of Lipid-Soluble Vitamins", Posters 11. Lipid Lowering Drug/Novel 72 nd EAS Congress, p. 90 (May 21-23, 2001)			

MM Best 4/1/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01	APPLICATION NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Duane A. Burnett et al.	
				FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
mb	NG	Kosoglou <i>et al.</i> , "Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs</i> , 72 nd EAS Congress, p. 38 (March 6-10, 2001)			
	NH	Bays <i>et al.</i> , "Low-Density Lipoprotein Cholesterol Reduction By SCH 58235 (Ezetimibe), A Novel Inhibitor of Intestinal Cholesterol Absorption, in 243 Hypercholesterolemic Subjects: Results of a Dose-Response Study", <i>XII International Symposium on Atherosclerosis, Stockholm, Sweden (June 25-29, 2000)</i>			
	NI	Castaner <i>et al.</i> , "Ezetimibe – Hypolipidemic Cholesterol Absorption Inhibitor", <i>Drugs of the Future</i> , 25(7):679-685 (2000)			
	NJ	Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by Ezetimibe (SCH 58235): Pooled Analysis of Two Phase II Studies", <i>American College of Cardiology Annual Meeting, Anaheim, CA (March 12-15, 2000)</i>			
	NK	Van Heek <i>et al.</i> , "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663", <i>British Journal of Pharmacology</i> , 129:1748-1754 (2000)			
	NL	Van Heek <i>et al.</i> , 2000, "The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically", <i>XII International Symposium of Atherosclerosis, Stockholm Sweden (June 25-29, 2000)</i>			
	NM	Iannucci <i>et al.</i> , "Metabolism of SCH 58235 in the Human, Rat and Dog", 47 th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX (June 13-17, 1999)			
	NN	Reiss <i>et al.</i> , "An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors", <i>Bioorganic & Medicinal Chemistry</i> , 7:2199-2202 (1999)			
	NO	Rosenblum <i>et al.</i> , "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", <i>J. Med. Chem.</i> 41:973-980 (1998)			
	NP	Vaccaro <i>et al.</i> , "Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8:313-318 (1998)			
	NQ	Zaks <i>et al.</i> , "Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235", <i>Applied Biochemistry and Biotechnology</i> , 73:205-214 (1998)			
	NR	W. Insull <i>et al.</i> , "Postmenopausal Hypercholesterolemic Women Derive Additive Benefit from Raloxifene and Simvastatin on Lipid Parameters", <i>World Heart Federation 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke – Abstract Book</i> , p. 35 (June 12-15, 2002)			
	NS	L. Simons <i>et al.</i> , 2002, "Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia: Efficacy and safety in patients with Type 2 diabetes mellitus", presented at the 38 th Annual Meeting of the EASD, September 1-5, 2002			
	NT	C. Allain <i>et al.</i> , 1974, "Enzymatic Determination of Total Serum Cholesterol", <i>Clinical Chemical</i> , 20:470-475			
mb	NU	R. Mayrhofer <i>et al.</i> , 1980, "Simple-Preparation of 3-Benzylidene-2-azetidinones", <i>Synthesis</i> , 247-248			





Mark Beer 4/1/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV06039US01	APPLICATION NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			APPLICANT: Duane A. Burnett et al.	
			FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	NV	Burrier, R.E. et al., 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", <i>Biochemical Pharmacology</i> 47:1545-1551		
	NW	Burrier, R.E. et al., 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibitor on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 272:156-163		
	NX	E.F. Binder et al., "Effects of Hormone Replacement Therapy on Serum Lipids in Elderly Women. A Randomized, Placebo-Controlled Trial", <i>134 Ann. Intern. Med.</i> 9:754-760 (May 1, 2001)		
	NY	MR Haymart et al., "Optimal Management of Dyslipidemia in Women and Men", <i>2 J. Gend. Specif. Med.</i> 6:37-42 (Nov. - Dec. 1997)		
	NZ	"Framingham Heart Study Analysis Reveals Some Primary Prevention Subgroups Are Being Overlooked", <i>Heartwire</i> (April 12, 2001)		
	OA	"Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third Report of the National Cholesterol Education Program (NCEP)", <i>NIH Publication No. 01-3670</i> (May 2001)		
	OB	Van Heek et al., "Ezetimibe, A Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters", <i>50 Diabetes</i> 1330-1335 (June 2001)		
	OC	"Additional Statins Show Anti-Inflammatory Effect", <i>103 Circulation</i> 1933-35 (April 17, 2001)		
	OD	H. Hauser, et al., "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine", <i>Biochemistry</i> 37:17843-17850, 1998		
	OE	G. Salen, et al., "Sitosterolemia", <i>Journal of Lipid Research</i> 33:945-955, 1992		
	OF	Stedman's Medical Dictionary, 27 th Edition, pg. 1381		
	OG	Stuart B. Rosenblum et al., Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, <i>J. Med. Chem.</i> 41:973-980 (1998)		
	OH	Remington's Pharmaceutical Sciences, 18 th ed. 1990 p. 1319, 1633-1647		
	OI	Baker S G et al., Treatment of homozygous familial hypercholesterolaemia with probucol, <i>South African Medical Journal</i> (1982)		
	OJ	R. Milanese et al., Xantom E Ipercolesterolemia: Prevalenza, Diagnosi e Terapia, <i>Chron. Derm.</i> 455-61 (1990)		
	OK	"Study showed ezetimibe significantly reduced levels of LDL cholesterol or "bad" cholesterol in patients" <i>Schering Press Release</i> 1-3 (2001)		
	OL	Kosoglou et al., "Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe" <i>Atherosclerosis</i> (2):3(2001)		
	OM	Davis et al., "The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs" <i>Metabolism</i> 50(10):1234-1241(2001)		
	ON	Thompson, G.R. et al., "Novel lipid-regulating drugs" <i>Expert Opinion on Investigational Drugs</i> 9(11):2619-2628 (2000), XP008011782 abstract; figure 8		
	OO	Kosoglou, T. et al., "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions" <i>Atherosclerosis</i> 2:89 (2001), XP001132089 abstract		
OP	Gilber R. Thompson et al., Novel lipid-regulating drugs, Ashley Publications Ltd. ISSN 1354-3784, 2000, pp. 2619-2628			
OQ	Belamarich P.F. et al., Response to diet and cholestyramine in a patient with sitosterolemia, <i>Pediatrics</i> , ISSN 0031-4005, Dec. 1990			
OR	Salen G. et al., Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis, <i>Journal of lipid research</i> , ISSN 0022-2275, Sept. 1985			

mmh Bud 4/1/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093US01	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: John R. Erbey II, et al.	
				FILING DATE: 11/04/2003	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
MB	OS	Sorbera <i>et al.</i> , Netoglitazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139			
	OT	Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259			
	OU	Berger <i>et al.</i> , Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology & Therapeutics</i> , 2002, 4:163-174			
	OV	U.S. Serial No. 10/791,910			
	OW	U.S. Serial No. 10/792,346			
	OX	U.S. Serial No. 10/791,979			
	OY	U.S. Serial No. 10/701,244			
	OZ	U.S. Serial No. 10/639,900			
	PA	Cholesterol Drugs May Reverse MS Symptoms, Studies in Mice show statins may treat Multiple Sclerosis – <i>CNN.com/Health</i> , Wednesday, November 6, 2002 posted: 4:30 PM EST (2130 GMT)			
	PB	D. Grady, Health, Antiolesterol Drug Found to Help Paralytic Mice, <i>www.nytimes.com/2002/11/07/health/07DRUG.html</i>			
	PC	S. Youssef <i>et al.</i> , Atorvastatin, a HMG-CoA Reductase Inhibitor, Promotes a Th2 Bias and Reversal of Paralysis in Chronic Relapsing Autoimmune Encephalomyelitis, <i>Neurology</i> 58 April 2002 (Suppl 3), A384-A385			
	PD	M. Soilu-Hanninen <i>et al.</i> , Semliki Forest Virus Infects Mouse Brain Endothelial Cells and Causes Blood-Brain Barrier Damage, <i>Journal of Virology</i> , Oct. 1994, 6291-6298			
	PE	Chapter 15 Animal Models for Autoimmune and Inflammatory Disease, Unit 15.1 Experimental Autoimmune Encephalomyelitis in the Mouse, <i>Current Protocols in Immunology</i> , November 6, 2002			
	PF	J. Pope <i>et al.</i> , Flow Cytometric and Functional Analyses of Central Nervous System-Infiltrating Cells in SJL/J Mice with Theiler's Virus-Induced Demyelinating Disease – Evidence for a CD4+ T Cell-Mediated Pathology, <i>The Journal of Immunology</i> 4050-4058			
	PG	H. Butzkueven <i>et al.</i> , LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival, 2002 <i>Nature Publishing Group- Nature Medicine</i> , 8:6 613-619 (June 2002)			
	PH	I. Grewal <i>et al.</i> , CD62L Is Required on Effector Cells for Local Interactions in the CNS to cause Myelin Damage in Experimental Allergic Encephalomyelitis, <i>Immunity</i> , 14:291-302 (March 2001)			
	PI	E. Tran <i>et al.</i> , Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein -1 α or its CCR5 Receptor, <i>Eur. J. Immunol.</i> , 30:1410-1415 (2000)			
	PJ	F. Giubilei <i>et al.</i> , Blood cholesterol and MRI activity in first clinical episode suggestive of simple sclerosis, <i>Aeta Neurol Scan</i> , 106:109-112 (2002)			
	PK	R.O. Weller, Neurology & Applied Neurobiology, <i>Blackwell Scientific Publications</i> , 20:2 April 1994			
PL	R. Berkow <i>et al.</i> , The Merck Manual of Medical Information – Home Edition, <i>Pocket Books</i> , Title of Chapter 68 347-350 (1997)				
PM	Pelfrey, C., Actrims – Ectrims 2002 (Part II), Baltimore, MD USA, 18-21- September 2002, <i>The Investigational Drugs Database ALERTS</i>				
PN	P. Reaney, Cholesterol Drugs may help MS Patients, <i>Yahoo Financial News</i> , Wednesday, November 6, 2002 pm ET				
PO	H. Wekerle, Tackling Multiple Sclerosis, <i>Nature</i> , 420:39-84 (2002)				
PP	S. Youssef <i>et al.</i> , The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease, <i>Nature</i> , 420:78-84 November 7, 2002				

Mark U. Bahr 4/11/06

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06039US01	APPLICATION NO.: 10/791,979
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Duane A. Burnett et al.	
(Use several sheets if necessary)				FILING DATE: 03/03/2004	GROUP: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	PQ	Shestopalov, A.M. et al., Cyclization of Nitriles .XI. Synthesis and reactions of 3-Amino-2-Carboxythieno[2,3-b]-Pyridines, <i>Zhurnal Organicheskoi Khimii</i> , 20:9 1818-1827			
	PR	Shestopalov, A. M. et al., Cyclization of Nitriles .XIX. Synthesis and reactions of the derivatives of 2-oxo-and 2-thioxo-2,5,6,7-Tetrahydro-1H-Pyridines, <i>Zhurnal Organicheskoi Khimii</i> 22:6 1163-1168			
EXAMINER				DATE CONSIDERED 	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					



6

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of
Invention

Substituted azetidinone compounds, processes for preparing
the same, formulations and uses thereof

Application Number: 10/791979



Confirmation Number: 4861

First Named Applicant: Duane Burnett

Attorney Docket Number: CV06039US01

Search string: (6191117 or 6191159 or 6200998 or 6207697
or 6207699 or 6207822 or 6214831 or 6235706
or 6245743 or 6248781 or 6251852 or 5827536
or 5827541 or 5831091 or 5843984 or 5846966
or 5847008 or 5847115 or 5851553 or 5856473
or 5858409 or 5859051 or 5862999 or 5866163
or 5869098 or 5871781 or 5880148 or 5883109
or 5886171 or 5919672 or 5925333 or 5952003
or 5952321 or 5959123 or 5972389 or 5976570
or 5985936 or 5990102 or 5998441 or 6027747
or 6043257 or 6056975 or 6057342 or 6063764
or 6066653 or 6071899 or 6074670 or 6080767
or 6080778 or 6084082).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
Y	1	6191117	2001-02-20	Kozachuk			
	2	6191159	2001-02-20	Pinto			
	3	6200998	2001-03-13	Sahoo			
	4	6207697	2001-03-27	Han			
	5	6207699	2001-03-27	Rothman			
	6	6207822	2001-03-27	Thiruvengadam			
	7	6214831	2001-04-10	Yokoo			
	8	6235706	2001-05-22	Gould			
	9	6245743	2001-06-12	Marlowe			
Y	10	6248781	2001-06-19	Jeppesen			

APP_ID=10791979

Mark Beer 4/1/06

11	6251852	2001-06-26	Gould
12	5827536	1998-10-27	Laruelle
13	5827541	1998-10-27	Yarwood
14	5831091	1998-11-03	Ohmizu
15	5843984	1998-12-01	Clay
16	5846966	1998-12-08	Rosenblum
17	5847008	1998-12-08	Doebber
18	5847115	1998-12-08	Iwasaki
19	5851553	1998-12-22	Myers
20	5856473	1999-01-05	Shankar
21	5858409	1999-01-12	Karetny
22	5859051	1999-01-12	Adams
23	5862999	1999-01-26	Czekai
24	5866163	1999-02-02	Myers
25	5869098	1999-02-09	Misra
26	5871781	1999-02-16	Myers
27	5880148	1999-03-09	Edgar
28	5883109	1999-03-16	Gregg
29	5886171	1999-03-23	Wu
30	5919672	1999-07-06	Homann
31	5925333	1999-07-20	Krieger
32	5952003	1999-09-14	Guentensberger
33	5952321	1999-09-14	Doherty
34	5959123	1999-09-28	Singh
35	5972389	1999-10-26	Shell
36	5976570	1999-11-02	Greaves
37	5985936	1999-11-16	Novak
38	5990102	1999-11-23	Hickey
39	5998441	1999-12-07	Palkowitz
40	6027747	2000-02-22	Terracol
41	6043257	2000-03-28	Dominguez
42	6056975	2000-05-02	Mitra
43	6057342	2000-05-02	Fevig
44	6063764	2000-05-16	Creasey
45	6066653	2000-05-23	Gregg
46	6071899	2000-06-06	Hickey

Mark Beal 4/11/06

104	47	6074670	2000-06-13	Stamm
	48	6080767	2000-06-27	Klein
	49	6080778	2000-06-27	Yankner
105	50	6084082	2000-07-04	Ravikumar

Signature

Examiner Name	Date
<i>Mark Beal</i>	<i>4/1/06</i>

6/30/04

Title of Invention	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
-----------------------	---

Application Number: 10/791979



Confirmation Number: 4861

First Named Applicant: Duane Burnett

Attorney Docket Number: CV06039US01

Search string: (6090830 or 6090839 or 6093812 or 6096883
or 6099865 or 6103705 or 6110493 or 6117429
or 6133001 or 6139873 or 6143885 or 5567439
or 5576014 or 5587172 or 5587180 or 5591456
or 5593971 or 5595761 or 5607697 or 5612353
or 5612367 or 5612378 or 5618707 or 5622719
or 5622985 or 5624920 or 5627176 or 5631023
or 5631365 or 5633246 or 5635210 or 5639475
or 5639739 or 5656624 or 5661145 or 5674893
or 5688785 or 5688787 or 5688990 or 5691375
or 5698527 or 5698548 or 5703234 or 5709886
or 5718388 or 5728827 or 5734077 or 5739321
or 5744467 or 5747001).pn.





US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
1	1	6090830	2000-07-18	Myers			
2	2	6090839	2000-07-18	Adams			
3	3	6093812	2000-07-25	Thiruvengadam			
4	4	6096883	2000-08-01	Wu			
5	5	6099865	2000-08-08	Augello			
6	6	6103705	2000-08-15	Uzan			
7	7	6110493	2000-08-29	Guentensberger			
8	8	6117429	2000-09-12	Bucci			
9	9	6133001	2000-10-17	Homann			
10	10	6139873	2000-10-31	Hughes			

Man Uzel

11	6143885	2000-11-07	Choi
12	5567439	1996-10-22	Myers
13	5576014	1996-11-19	Mizumoto
14	5587172	1996-12-24	Cherukuri
15	5587180	1996-12-24	Allen
16	5591456	1997-01-07	Franson
17	5593971	1997-01-14	Tschollar
18	5595761	1997-01-21	Allen
19	5607697	1997-03-04	Alkire
20	5612353	1997-03-18	Ewing
21	5612367	1997-03-18	Timko
22	5612378	1997-03-18	Tianbao
23	5618707	1997-04-08	Homann
24	5622719	1997-04-22	Myers
25	5622985	1997-04-22	Olukotun
26	5624920	1997-04-29	McKittrick
27	5627176	1997-05-06	Kirkup
28	5631023	1997-05-20	Kearney
29	5631365	1997-05-20	Rosenblum
30	5633246	1997-05-27	McKittrick
31	5635210	1997-06-03	Allen
32	5639475	1997-06-17	Bettman
33	5639739	1997-06-17	Dominguez
34	5656624	1997-08-12	Vaccaro
35	5661145	1997-08-26	Davis
36	5674893	1997-10-07	Behounek
37	5688785	1997-11-18	Vaccaro
38	5688787	1997-11-18	Burnett
39	5688990	1997-11-18	Shankar
40	5691375	1997-11-25	Behounek
41	5698527	1997-12-16	Kim
42	5698548	1997-12-16	Dugar
43	5703234	1997-12-30	Iwasaki
44	5709886	1998-01-20	Bettman
45	5718388	1998-02-17	Czekai
46	5728827	1998-03-17	Kannapan

	47	5734077	1998-03-31	Regnier
	48	5739321	1998-04-14	Wu
	49	5744467	1998-04-28	McKittrick
	50	5747001	1998-05-05	Wiedmann

Signature

Mark Best 4/1/06

Examiner Name	Date

6/30/04

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
--------------------	--

Application Number: 10/791979



Confirmation Number: 4861

First Named Applicant: Duane Burnett

Attorney Docket Number: CV06039US01

Search string: (5753254 or 5756470 or 5759865 or 5767115 or 5776491 or 5807576 or 5807577 or 5807578 or 5807834 or 5808056 or 5817806 or 4952689 or 4961890 or 4983597 or 4990535 or 5030628 or 5073374 or 5091525 or 5099034 or 5100675 or 5112616 or 5120729 or 5130333 or 5145684 or 5157025 or 5162117 or 5178878 or 5188825 or 5190970 or 5204461 or 5219574 or 5223264 or 5229362 or 5229381 or 5229510 or 5260305 or 5286631 or 5298497 or 5306817 or 5318767 or 5348953 or 5350868 or 5384124 or 5399363 or 5401513 or 5412092 or 5429824 or 5446464 or 5461039 or 5464632).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
MP	1	5753254	1998-05-19	Khan			
	2	5756470	1998-05-26	Yumibe			
	3	5759865	1998-06-02	Bruts			
	4	5767115	1998-06-16	Rosenblum			
	5	5776491	1998-07-07	Allen			
	6	5807576	1998-09-15	Allen			
	7	5807577	1998-09-15	Quali			
	8	5807578	1998-09-15	Acosta-Cuello			
	9	5807834	1998-09-15	Morehouse			
MP	10	5808056	1998-09-15	Amato			

Man Usher 4/1/06

W2	11	5817806	1998-10-06	Rossi
	12	4952689	1990-08-28	Kawashima
	13	4961890	1990-10-09	Boyer
	14	4983597	1991-01-08	Yang
	15	4990535	1991-02-05	Cho
	16	5030628	1991-07-09	Joyeau
	17	5073374	1991-12-17	McCarty
	18	5091525	1992-02-25	Brennan
	19	5099034	1992-03-24	Yoshida
	20	5100675	1992-03-31	Cho
	21	5112616	1992-05-12	McCarty
	22	5120729	1992-06-09	Chabala
	23	5130333	1992-07-14	Pan
	24	5145684	1992-09-08	Liversidge
	25	5157025	1992-10-22	Aberg
	26	5162117	1992-11-10	Stupak
	27	5178878	1993-01-12	Wehling
	28	5188825	1993-02-23	Iles
	29	5190970	1993-03-02	Pan
	30	5204461	1993-04-20	Murayama
	31	5219574	1993-06-15	Wehling
	32	5223264	1993-06-29	Wehling
	33	5229362	1993-07-20	Kirst
	34	5229381	1993-07-20	Doherty
	35	5229510	1993-07-20	Knight
	36	5260305	1993-11-09	Dennick
	37	5286631	1994-02-15	Boeck
	38	5298497	1994-03-29	Tschollar
	39	5306817	1994-04-26	Thiruvengadam
	40	5318767	1994-06-07	Liversidge
	41	5348953	1994-09-20	Doherty
	42	5350868	1994-09-27	Yoshida
	43	5384124	1995-01-24	Courtelle
	44	5399363	1995-03-21	Liversidge
	45	5401513	1995-03-28	Wehling
W2	46	5412092	1995-05-02	Rey

Man Beer 4/1/06

<input checked="" type="checkbox"/>	47	5429824	1995-07-04	June
<input type="checkbox"/>	48	5446464	1995-08-29	Feldle
<input type="checkbox"/>	49	5461039	1995-10-24	Tschollar
<input checked="" type="checkbox"/>	50	5464632	1995-11-07	Cousin

Signature

Examiner Name	Date
<i>Theresa Bern</i>	<i>4/1/06</i>

6/30/04

Electronic Version v18
Stylesheet Version v18.0

Title of Invention	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof																																																																																																				
<p>Application Number: 10/791979</p> <p>Confirmation Number: 4861</p> <p>First Named Applicant: Duane Burnett</p> <p>Attorney Docket Number: CV06039US01</p> <p>Search string: (5494683 or 5503846 or 5510118 or 5510466 or 5518187 or 5518738 or 5545628 or 5550229 or 5552160 or 5561227 or 5563264).pn.</p> <p>US Patent Documents</p> <p>Note: Applicant is not required to submit a paper copy of cited US Patent Documents</p> <table border="1"><thead><tr><th>init</th><th>Cite.No.</th><th>Patent No.</th><th>Date</th><th>Patentee</th><th>Kind</th><th>Class</th><th>Subclass</th></tr></thead><tbody><tr><td>W/1</td><td>1</td><td>5494683</td><td>1996-02-27</td><td>Liversidge</td><td></td><td></td><td></td></tr><tr><td></td><td>2</td><td>5503846</td><td>1996-04-02</td><td>Wehling</td><td></td><td></td><td></td></tr><tr><td></td><td>3</td><td>5510118</td><td>1996-04-23</td><td>Bosch</td><td></td><td></td><td></td></tr><tr><td></td><td>4</td><td>5510466</td><td>1996-04-23</td><td>Krieger</td><td></td><td></td><td></td></tr><tr><td></td><td>5</td><td>5518187</td><td>1996-05-21</td><td>Bruno</td><td></td><td></td><td></td></tr><tr><td></td><td>6</td><td>5518738</td><td>1996-05-21</td><td>Eickhoff</td><td></td><td></td><td></td></tr><tr><td></td><td>7</td><td>5545628</td><td>1996-08-13</td><td>Deboeck</td><td></td><td></td><td></td></tr><tr><td></td><td>8</td><td>5550229</td><td>1996-08-27</td><td>Iwasaki</td><td></td><td></td><td></td></tr><tr><td></td><td>9</td><td>5552160</td><td>1996-09-03</td><td>Liversidge</td><td></td><td></td><td></td></tr><tr><td></td><td>10</td><td>5561227</td><td>1996-10-01</td><td>Thiruvengadam</td><td></td><td></td><td></td></tr><tr><td>W/3</td><td>11</td><td>5563264</td><td>1996-10-08</td><td>Kume</td><td></td><td></td><td></td></tr></tbody></table> <p>Signature</p> <table border="1"><thead><tr><th>Examiner Name</th><th>Date</th></tr></thead><tbody><tr><td><i>Mun Bah</i></td><td>4/1/06</td></tr></tbody></table>		init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass	W/1	1	5494683	1996-02-27	Liversidge					2	5503846	1996-04-02	Wehling					3	5510118	1996-04-23	Bosch					4	5510466	1996-04-23	Krieger					5	5518187	1996-05-21	Bruno					6	5518738	1996-05-21	Eickhoff					7	5545628	1996-08-13	Deboeck					8	5550229	1996-08-27	Iwasaki					9	5552160	1996-09-03	Liversidge					10	5561227	1996-10-01	Thiruvengadam				W/3	11	5563264	1996-10-08	Kume				Examiner Name	Date	<i>Mun Bah</i>	4/1/06
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass																																																																																														
W/1	1	5494683	1996-02-27	Liversidge																																																																																																	
	2	5503846	1996-04-02	Wehling																																																																																																	
	3	5510118	1996-04-23	Bosch																																																																																																	
	4	5510466	1996-04-23	Krieger																																																																																																	
	5	5518187	1996-05-21	Bruno																																																																																																	
	6	5518738	1996-05-21	Eickhoff																																																																																																	
	7	5545628	1996-08-13	Deboeck																																																																																																	
	8	5550229	1996-08-27	Iwasaki																																																																																																	
	9	5552160	1996-09-03	Liversidge																																																																																																	
	10	5561227	1996-10-01	Thiruvengadam																																																																																																	
W/3	11	5563264	1996-10-08	Kume																																																																																																	
Examiner Name	Date																																																																																																				
<i>Mun Bah</i>	4/1/06																																																																																																				

6/30/04

Title of Invention	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
-----------------------	---

Application Number: 10/791979



Confirmation Number: 4861

First Named Applicant: Duane Burnett

Attorney Docket Number: CV06039US01

Search string: (6030990 or 6166049 or 5021461 or 4687777
or 3716583 or 3781328 or 3948973 or 4072705
or 4075000 or 4144232 or 4178695 or 4179515
or 4235896 or 4250191 or 4260743 or 4304718
or 4375475 or 4443372 or 4444784 or 4472309
or 4479900 or 4500456 or 4534786 or 4564609
or 4576748 or 4576749 or 4576753 or 4581170
or 4595532 or 4602003 or 4602005 or 4614614
or 4616047 or 4620867 or 4633017 or 4642903
or 4675399 or 4680391 or 4739101 or 4778883
or 4784734 or 4794108 or 4800079 or 4803266
or 4834846 or 4814354 or 4871752 or 4876365
or 4879301 or 4895726 or 20030153541 or
20020132855 or 20020137689 or 20020128253
or 20020039774 or 20020128252 or
20030013729 or 20030105028 or 20030053981
or 20020183305 or 20020169134 or
20030013699 or 20020151536 or 20020192203
or 20030069221 or 20030119757 or
20020147184 or 20030119796 or 20030119809
or 20030119808 or 20030119428).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
1	1	6030990	2000-02-29	Maeda			
2	2	6166049	2000-12-26	Smith			
3	3	5021461	1991-06-04	Robinson			
4	4	4687777	1987-08-18	Meguro			

MWZBein 4/11/06

5	3716583	1973-02-13	Nakamura
6	3781328	1973-12-25	Witte
7	3948973	1976-04-06	Phillips
8	4072705	1978-02-07	Mieville
9	4075000	1978-02-21	Abdulla
10	4144232	1979-03-13	Koppel
11	4178695	1979-12-18	Erbeia
12	4179515	1979-12-18	Mieville
13	4235896	1980-11-25	Mieville
14	4250191	1981-02-10	Edwards
15	4260743	1981-04-07	Bose
16	4304718	1981-12-08	Kamiya
17	4375475	1983-03-01	Willard
18	4443372	1984-04-17	Luo
19	4444784	1984-04-24	Hoffman
20	4472309	1984-09-18	Kamiya
21	4479900	1984-10-30	Luo
22	4500456	1985-02-19	Spitzer
23	4534786	1985-08-13	Luo
24	4564609	1986-01-14	Tamura
25	4576748	1986-03-18	Greenlee
26	4576749	1986-03-18	Zahler
27	4576753	1986-03-18	Kamiya
28	4581170	1986-04-08	Mueller
29	4595532	1986-06-17	Miller
30	4602003	1986-07-22	Mallinow
31	4602005	1986-07-22	Malinow
32	4614614	1986-09-30	Ernest
33	4616047	1986-10-07	Lafon
34	4620867	1986-11-04	Luo
35	4633017	1986-12-30	Mueller
36	4642903	1987-02-17	Davies
37	4675399	1987-06-23	Miller
38	4680391	1987-07-14	Firestone
39	4739101	1988-04-19	Bourgogne
40	4778883	1988-10-18	Yoshioka

41	4784734	1988-11-15	Torii
42	4794108	1988-12-27	Kishimoto
43	4800079	1989-01-24	Boyer
44	4803266	1989-02-07	Kawashima
45	4834846	1989-05-30	Abramson
46	4814354	1989-03-21	Ghebre-Sellassie
47	4871752	1989-10-03	Zermatter
48	4876365	1989-10-24	Kirkup
49	4879301	1989-11-07	Umio
50	4895726	1990-01-23	Curtet

US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
10	1	20030153541	2003-08-14	Dudley			
	2	20020132855	2002-09-19	Nelson			
	3	20020137689	2002-09-26	Glombik			
	4	20020128253	2002-09-12	Glombik			
	5	20020039774	2002-04-04	Kramer			
	6	20020128252	2002-09-02	Glombik			
	7	20030013729	2003-01-16	Iqbal			
	8	20030105028	2003-06-05	Schering Corporation			
	9	20030053981	2003-03-20	Schering Corporation			
	10	20020183305	2002-12-05	Schering Corporation			
	11	20020169134	2002-11-14	Schering Corporation			
	12	20030013699	2003-01-16	Schering Corporation			
	13	20020151536	2002-10-17	Schering Corporation			
	14	20020192203	2002-12-19	Schering Corporation			
	15	20030069221	2003-04-10	Schering Corporation			
	16	20030119757	2003-06-26	Schering Corporation			
	17	20020147184	2002-10-10	Schering Corporation			
	18	20030119796	2003-06-26	Schering Corporation			
	19	20030119809	2003-06-26	Schering Corporation			
	20	20030119808	2003-06-26	Schering Corporation			
10	21	20030119428	2003-06-26	Schering Corporation			

Signature

Examiner Name	Date
<i>Min (Ben)</i>	<i>4/1/06</i>

Electronic Version v18
Stylesheet Version v18.0

6/30/04

Title of Invention	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
--------------------	--

Application Number: 10/791979



Confirmation Number: 4861

First Named Applicant: Duane Burnett

Attorney Docket Number: CV06039US01

Search string: (4925672 or 4939248 or 4166907 or 6262042 or 6262047 or 6262098 or 6242605 or 6277584 or 6316029 or RE37721 or H0001286 or 2809194 or 3108097 or 3152173 or 3267104 or 3399192 or 3692895 or 4148923 or 4239763 or 4567195 or 4626549 or 4654362 or 4680289 or 4937267 or 5093365 or 5106833 or 5110730 or 5120713 or 5278176 or 5358852 or 5385885 or 5703188 or 5994554 or 6008237 or 6028109 or 6033656 or 6040147 or 6121319 or 6127424 or 6140354 or 6147090 or 6147109 or 6147250 or 6159997 or 6162805 or 6166049 or 6174665 or 6180138 or 6180625 or 6180660 or 20010028895 or 20020006919),pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
<input checked="" type="checkbox"/>	1	4925672	1990-05-15	Gremm			
<input checked="" type="checkbox"/>	2	4939248	1990-07-03	Yoshioka			
<input checked="" type="checkbox"/>	3	4166907	1979-09-04	Krapcho			
<input checked="" type="checkbox"/>	4	6262042	2001-07-17	Cook			
<input checked="" type="checkbox"/>	5	6262047	2001-07-17	Zhu			
<input checked="" type="checkbox"/>	6	6262098	2001-07-17	Huebner			
<input checked="" type="checkbox"/>	7	6242605	2001-06-05	Raveendranath			
<input checked="" type="checkbox"/>	8	6277584	2001-08-21	Chu			
<input checked="" type="checkbox"/>	9	6316029	2001-11-13	Jain			
<input checked="" type="checkbox"/>	10	RE37721	2002-05-28	Rosenblum			

APP_ID=10791979

Mark Baer 4/1/06

Page 1 of 3

103	11	H0001286	1994-02-01	Eisman
	12	2809194	1957-10-08	Novello
	13	3108097	1963-10-22	Ugi
	14	3152173	1964-10-06	Ehrhart
	15	3267104	1966-08-16	Hermans
	16	3399192	1968-08-27	Regnier
	17	3692895	1972-09-19	Nelson
	18	4148923	1979-04-10	Giudicelli
	19	4239763	1980-12-16	Milavec
	20	4567195	1986-01-28	Schwarz
	21	4626549	1986-12-02	Molloy
	22	4654362	1987-03-31	Lommen
	23	4680289	1987-07-14	Applezweig
	24	4937267	1990-06-26	Holloway
	25	5093365	1992-03-03	Berge
	26	5106833	1992-04-21	Broze
	27	5110730	1992-05-05	Edgington
	28	5120713	1992-06-09	Mugica
	29	5278176	1994-01-11	Lin
	30	5358852	1994-10-25	Wu
	31	5385885	1995-01-31	Gasic
	32	5703188	1997-12-30	Mandeville
	33	5994554	1999-11-30	Kliewer
	34	6008237	1999-12-28	Sahoo
	35	6028109	2000-02-22	Wilson
	36	6033656	2000-03-07	Mikami
	37	6040147	2000-03-21	Ridker
	38	6121319	2000-09-19	Somers
	39	6127424	2000-10-03	Martin
	40	6140354	2000-10-31	Dax
	41	6147090	2000-11-14	DeNinno
	42	6147109	2000-11-14	Liao
	43	6147250	2000-11-14	Somers
	44	6159997	2000-12-12	Tsujita
	45	6162805	2000-12-19	Hefti
103	46	6166049	2000-12-26	Smith

47	6174665	2000-01-16	Dullien
48	6180138	2001-01-30	Engh
49	6180625	2001-01-30	Persson
50	6180660	2001-01-30	Whitney


US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
1	1	20010028895	2002-10-11	Bisgaier			
2	2	20020006919	2002-01-17	Thosar			

Signature

Examiner Name	Date
<i>M. M. Beer</i>	4/1/06



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*ATTY. DOCKET NO.:
CV06039US01APPLICATION NO.:
10/791,979APPLICANT:
Duane A. Burnett, et al.FILING DATE:
03/03/2004GROUP:
To Be Assigned**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

WB	AQ	T. Kosoglou et al., "CoAdministration of Simvastatin and Ezetimibe Leads to Significant Reduction in LDL-Cholesterol", Proceedings of 3 rd International Congress on Coronary, Artery Disease from Prevention to Intervention, Lyon, France p. 271 (2000), XP008027568
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER

Mark Bar

DATE CONSIDERED

4/1/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.